Literature DB >> 6454675

Cefoperazone and cefotiam--two new cephalosporins: an in-vitro comparison.

R Wise, J M Andrews, K A Bedford.   

Abstract

The in vitro activity of cefoperazone (CPZ) and cefotiam (CTM) was compared to other available cephalosporins. Using an agar dilution procedure both CTM and CPZ were more active against the Enterobacteriaceae tested than cefoxitin, cefuroxime and cefazolin; CTM being slightly more active than CPZ, in particular against Klebsiella spp Haemophilus influenzae were more susceptible to CPZ. CTM had no activity against Pseudomonas aeruginosa but CPZ exhibited considerable activity (mode MIC 4 mg/l). Against Bacteroides fragilis CPZ had a similar activity to cefuroxime, but CTM was less active. CTM was about twice as active as CPZ against Staphylococcus aureus, cefazolin being the most active agent tested. The MBC was about twice the MIC for each compound and the presence of 75% serum had only a modest effect on the MIC and MBC. The protein binding of CPZ was 94% and CTM 62%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454675     DOI: 10.1093/jac/7.4.343

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Pharmacokinetics of cefotiam in humans.

Authors:  M C Rouan; J B Lecaillon; J Guibert; J Modai; J P Schoeller
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

2.  Pharmacokinetics of cefotiam in normal humans.

Authors:  F D Daschner; K A Hemmer; P Offermann; J Slanicka
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

3.  Skin tissue fluid levels of cefotiam in healthy man following oral cefotiam hexetil.

Authors:  H C Korting; M Schäfer-Korting; F Kees; A Lukacs; H Grobecker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of cefotiam.

Authors:  J M Brogard; F Jehl; B Willemin; A M Lamalle; J F Blickle; H Monteil
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.